STING1 and acute myeloid leukemia: STING agonists activate cGAS–STING signaling, inducing type-I interferon programs that re-prime mitochondrial apoptosis and enhance antigen presentation, particularly in TP53-mutant AML, where DNA-damage and kinase therapies often fail.